News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Transcept Pharmaceuticals, Inc. (TSPT) to Report Fourth Quarter and Full Year 2012 Financial Results and Host Conference Call on February 27, 2013



2/21/2013 6:33:02 AM

POINT RICHMOND, Calif., Feb. 21, 2013 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that the company will host a conference call on Wednesday, February 27, 2013, at 4:30 p.m. Eastern Time to discuss its fourth quarter and full year 2012 financial results. The conference call will follow the release of the Transcept fourth quarter and full year 2012 financial results after the close of market that day.

Conference Call Information


Date: Wednesday, February 27, 2013


Time: 4:30 p.m. ET


Dial-in (U.S.): 877-638-4558


Dial-in (International): 914-495-8537

A simultaneous webcast of the conference call will be available on the Investors section of the Transcept website at www.transcept.com. A replay of this webcast will be available on the website shortly after the conclusion of the call through March 31, 2013.

About Transcept
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue Pharma holds commercialization and development rights for Intermezzo in the United States. For further information about Transcept, please visit www.transcept.com. For information about Intermezzo, please visit www.MyIntermezzo.com.

Contact:
Transcept Pharmaceuticals, Inc.
Greg Mann
Sr. Director, Corporate Communications
(510) 215-3567
gmann@transcept.com

SOURCE Transcept Pharmaceuticals, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES